Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD | Learning | The JAMA Network
[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
×